Medtronic And Titan Medical Sign Licensing, Development Agreements For Robotic Surgeries
Executive Summary
Medtronic has agreed to licensing and development agreements with cash-strapped surgical robotics company Titan receiving payments up to $31m pending certain milestones.
You may also be interested in...
Medtronic Sales Slump In Q4 2020 But CEO Reveals Appetite For Tuck-In Acquisitions
Medtronic's revenue for the fourth quarter of fiscal 2020 was down 25% year-year-over due to the COVID-19 pandemic. The hardest-hit segment was restorative therapies, which reported a 33% year-over-year decline in the quarter due to the drop off in deferrable procedures and capital purchases. For the full fiscal year, Medtronic's revenue was down 4.2% to $28.9bn.
Newer Therapy Areas Will Drive Women’s Health Funding In 2024
Women’s health startups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors in 2024. Meanwhile, machine learning and AI, as well as next-generation treatments such as psychedelic therapy, stand to drive advancements in the space.
News We’re Watching: Boston Scientific Closes Relievant, Medtronic's PFA Earns CE Mark, And More
Medtech Insight's News We're Watching highlights medtech industry news developments you may have missed over the last few weeks.